<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasia</z:hpo> developed 14 to 189 months after diagnosis of the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in 12 out of 3365 children treated for <z:e sem="disease" ids="C1698088" disease_type="Neoplastic Process" abbrv="">malignant solid tumours</z:e>; 6 of the 12 were in their first complete remission </plain></SENT>
<SENT sid="1" pm="."><plain>The 10-year cumulative incidence of myeloid <z:hpo ids='HP_0002664'>neoplasia</z:hpo> was 1.3% (95% Cl 0.5-3.6) for the 447 patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, 1.3% (0.4-4.3) for the 420 with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 1.2% (0.3-5.2) for the 440 with <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This complication appeared in 1 of 180 children with <z:e sem="disease" ids="C0006118" disease_type="Neoplastic Process" abbrv="">brain tumours</z:e> and in none of the 1878 with other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Risk of therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> was associated with recurrence of the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, a combination of radiotherapy and chemotherapy with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, and age greater than or equal to 12 years at diagnosis of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 8 patients who underwent chromosomal analysis of neoplastic myeloid cells, 2 showed complete loss of chromosome 7 and 4 showed t(9;11) or t(8;21) with or without del(16)(q22) </plain></SENT>
<SENT sid="5" pm="."><plain>The 2 patients who had received an epipodophyllotoxin had an 11q23 abnormality </plain></SENT>
<SENT sid="6" pm="."><plain>The risk of therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasia</z:hpo> is low in children with <z:e sem="disease" ids="C1698088" disease_type="Neoplastic Process" abbrv="">malignant solid tumours</z:e> </plain></SENT>
</text></document>